The group's principal activity is to specialize in the development of oral and nasal delivery of vaccines and drugs. The group develops a proprietary oral and nasal vaccine delivery technology called the microvax(tm)) system. This system is used in biodefense vaccines, including nasal vaccines against ricin toxins and anthrax and an oral delivered vaccine against botulinum toxin. The group also develops orbec(R), an oral therapeutic product, for the treatment of intestinal graft-vs-host. The group develops oral drug delivery systems, named the lpm(tm), plp(tm) and lpe(tm) systems, for the delivery of proteins and water insoluble drugs. The group has preclinical animal data demonstrating the oral delivery of the drug leuprolide and paclitaxel.
